Mikhail Blagosklonny’s Contributions in the Cancer Research Field
About Mikhail Blagosklonny
Mikhail Blagosklonny is a renowned professor, researcher, and philanthropist. He devotes to helping individuals around the world to access quality treatment regardless of their economic status. As a researcher, Mikhail has interest in the field of medical research and focuses on the study of cancer and age-related diseases. He is interested in unraveling the connection between cancer and age and the reason why cancer is more common among the older individuals. Over time, Mikhail Blagosklonny continues to research the oncology field.Mikhail is influential as not only a professor but also a researcher and philanthropist within the world of oncology. He has been an inspiration to his students and peers who would want to advance his studies in the future. Mikhail Blagosklonny’s studies regarding cancer and age have earned it a good reputation within medical field. His mission is to create health models to not only treat cancer but find an effective cancer treatment that will not be expensive and excruciating as the current treatments.Mikhail hopes to develop a model in which doctors will eliminate cancerous cells within the body without destroying healthy cells.
As such, cells that are crucial to recovering the body and mind after years of cancer treatment won’t be affected.Over time, Mikhail Blagosklonny has made significant progress in the field of oncology. Mikhail hopes his findings will inspire his peers and students around the world to conduct further studies regarding the connection between cancer and age. He believes that treatment for cancer, a tragic and chronic disease, will not be a luxury treatment for the wealthy, but an easy and affordable treatment.Mikhail Blagosklonny holds a Ph.D. in Experimental Medicine and Cardiology and Master’s Degree in Internal Medicine from the First Pavlov State Medical University. In 2002, New York Medical College appointed him as an associate professor of medicine before making his way up as a senior scientist at Ordway Research Institute. He held this position until 2009 before leaving for Roswell Park Cancer Institute as professor of oncology. Mikhail’s research interests include cancer and cancer therapies that don’t damage healthy cells. Mikhail Blagosklonny has recently formulated a hypothesis about the possible use of TOR signaling in cancer treatment. He has also proposed the use of rapamycin, a common cancer drug as a possible remedy for life extension. Mikhail is considered as one of the advocates of rapamycin as a possible treatment for life extension.
Besides his role as a researcher and philanthropist, Mikhail Blagosklonny serves as editor-in-chief of Aging, Cell Cycle, and Oncotarget. He is also a member of the editorial board of Cell Death & Differentiation as well as associate editor of Cancer Biology & Therapy.
Oncotarget is a peer-reviewed journal that focuses on cancer-related research. Recently, Oncotarget has expanded into cardiology and neurology research. It aims to distribute research results quickly and to a wide audience. Established in 2010, Oncotarget is a weekly peer-reviewed publication that is freely accessed on the internet.